Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 26, 2021 10:39am
228 Views
Post# 33604115

RE:RE:RE:Re: Time the take the diapers off

RE:RE:RE:Re: Time the take the diapers off
Yellowknifer69 wrote: Hey Mugsy

Still kicking in Canada!  undoubtedly, there has been a cringe-worthy lack of news from our team at ATE.  But, if past history is anything to count on we are due for a news release from Dan soon?

Summer doldrums for sure. I guess for many bashers /investors no news means beat the shite out of each other, eh?!

Yellowknifer


hahaha!

As we head into the quiet part of negotiations, I would think there are some very serious discussions underway and the number of participants/depth of interest ... is very much left to the imagination.

I’d also like to believe ATE is proving out their new-found approach to drug development ... tweaking the process.  Maybe at some point we get a little “show and tell” with respect to how it’s working.

It will be nice to eventually get a P3 plan with set dosing.  That should spark some new excitement.

So - quiet yes - but I highly doubt it’s slow.  Just not obvious ... yet.

Yes - I do think we are overdue for an update.  

<< Previous
Bullboard Posts
Next >>